Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Optimal Two-stage Designs with Consideration of Response and Safety and Their Correlation

Bayesian Optimal Phase II Design for Randomized Clinical Trials

Optimal, minimax and admissible two-stage design for phase II oncology clinical trials

Bayesian Optimal Phase II Designs with Dual‐criterion Decision Making

BOP2: Bayesian Optimal Design for Phase II Clinical Trials with Simple and Complex Endpoints.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Optimal Sequential Enrichment Designs for Phase II Clinical Trials.

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

Bayesian Optimal Interval Designs for Phase I Clinical Trials

Multi-stage Design in Phase Ⅱ Clinical Trials for Anti-Cancer Drug Development

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

An Optimization Algorithm for Designing Phase I Cancer Clinical Trials

Utpi: A Utility‐based Toxicity Probability Interval Design for Phase I/II Dose‐finding Trials

Optimal curtailed designs for single arm phase II clinical trials

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

A Bayesian Piecewise Exponential Phase II Design for Monitoring a Time‐to‐event Endpoint

Two-phase designs with failure time processes subject to nonsusceptibility

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Comparative review of novel model-assisted designs for phase I clinical trials.

Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints